CANDEL THERAPEUTICS, INC. (CADL) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value |
| Current obligations | 12.69M USD | Liabilities, Current |
| Cash and equivalents | 201.56M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $12.69M | $201.56M | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $7.05M | $194.83M | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $9.00M | $119.73M | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $10.93M | $86.96M | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $14.71M | $100.69M | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $20.07M | $92.17M | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $37.53M | $102.65M | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $15.27M | $16.56M | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $14.00M | $21.45M | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $13.54M | $25.71M | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $14.18M | $35.41M | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $10.33M | $42.98M | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $8.16M | $51.89M | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $5.24M | $59.26M | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $5.62M | $70.06M | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $5.90M | $77.18M | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $5.88M | $86.78M | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $5.47M | $94.32M | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $5.36M | $82.64M | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $4.40M | $88.39M | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $4.49M | $24.32M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $4.71M | $35.05M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |